Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth

Martin O. Savage, Vivian Hwa, Alessia David, Ronald (Ron) Rosenfeld, Louise A. Metherell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Human genetic defects in the growth hormone (GH)-IGF-I axis affecting the IGF system present with growth failure as their principal clinical feature. This is usually associated with GH insensitivity (GHI) presenting in childhood as severe or mild short stature. Dysmorphic features and metabolic abnormalities may also be present. The field of GHI due to mutations affecting GH action has evolved rapidly since the first description of the extreme phenotype related to homozygous GH receptor (GHR) mutations in 1966. A continuum of genetic, phenotypic, and biochemical abnormalities can be defined associated with clinically relevant defects in linear growth. The mechanisms of the GH-IGF-I axis in the regulation of normal human growth is discussed followed by descriptions of mutations in GHR, STAT5B, IGF-I, IGFALS, IGF1R, and GH1 defects causing bio-inactive GH or anti-GH antibodies. These GHIGF-I axis defects are associated with a range of clinical, and hormonal characteristics. An up-dated approach to the clinical assessment of the patient with GHI focusing on investigation of the GH-IGF-I axis and relevant molecular studies contributing to the identification of causative genetic defects is also discussed.

Original languageEnglish (US)
Article numberArticle 95
JournalFrontiers in Endocrinology
Volume2
Issue numberDEC
DOIs
StatePublished - 2011

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Growth
Mutation
Somatotropin Receptors
IGF Type 1 Receptor
Medical Genetics
Molecular Biology
Phenotype
Antibodies

Keywords

  • Childhood linear growth
  • Genetic defects
  • Growth hormone insensitivity
  • Growth hormone-IGF-I axis mutations

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth. / Savage, Martin O.; Hwa, Vivian; David, Alessia; Rosenfeld, Ronald (Ron); Metherell, Louise A.

In: Frontiers in Endocrinology, Vol. 2, No. DEC, Article 95, 2011.

Research output: Contribution to journalArticle

Savage, Martin O. ; Hwa, Vivian ; David, Alessia ; Rosenfeld, Ronald (Ron) ; Metherell, Louise A. / Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth. In: Frontiers in Endocrinology. 2011 ; Vol. 2, No. DEC.
@article{4cdeae1dd35c42a998a74c862b444164,
title = "Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth",
abstract = "Human genetic defects in the growth hormone (GH)-IGF-I axis affecting the IGF system present with growth failure as their principal clinical feature. This is usually associated with GH insensitivity (GHI) presenting in childhood as severe or mild short stature. Dysmorphic features and metabolic abnormalities may also be present. The field of GHI due to mutations affecting GH action has evolved rapidly since the first description of the extreme phenotype related to homozygous GH receptor (GHR) mutations in 1966. A continuum of genetic, phenotypic, and biochemical abnormalities can be defined associated with clinically relevant defects in linear growth. The mechanisms of the GH-IGF-I axis in the regulation of normal human growth is discussed followed by descriptions of mutations in GHR, STAT5B, IGF-I, IGFALS, IGF1R, and GH1 defects causing bio-inactive GH or anti-GH antibodies. These GHIGF-I axis defects are associated with a range of clinical, and hormonal characteristics. An up-dated approach to the clinical assessment of the patient with GHI focusing on investigation of the GH-IGF-I axis and relevant molecular studies contributing to the identification of causative genetic defects is also discussed.",
keywords = "Childhood linear growth, Genetic defects, Growth hormone insensitivity, Growth hormone-IGF-I axis mutations",
author = "Savage, {Martin O.} and Vivian Hwa and Alessia David and Rosenfeld, {Ronald (Ron)} and Metherell, {Louise A.}",
year = "2011",
doi = "10.3389/fendo.2011.00095",
language = "English (US)",
volume = "2",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "DEC",

}

TY - JOUR

T1 - Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth

AU - Savage, Martin O.

AU - Hwa, Vivian

AU - David, Alessia

AU - Rosenfeld, Ronald (Ron)

AU - Metherell, Louise A.

PY - 2011

Y1 - 2011

N2 - Human genetic defects in the growth hormone (GH)-IGF-I axis affecting the IGF system present with growth failure as their principal clinical feature. This is usually associated with GH insensitivity (GHI) presenting in childhood as severe or mild short stature. Dysmorphic features and metabolic abnormalities may also be present. The field of GHI due to mutations affecting GH action has evolved rapidly since the first description of the extreme phenotype related to homozygous GH receptor (GHR) mutations in 1966. A continuum of genetic, phenotypic, and biochemical abnormalities can be defined associated with clinically relevant defects in linear growth. The mechanisms of the GH-IGF-I axis in the regulation of normal human growth is discussed followed by descriptions of mutations in GHR, STAT5B, IGF-I, IGFALS, IGF1R, and GH1 defects causing bio-inactive GH or anti-GH antibodies. These GHIGF-I axis defects are associated with a range of clinical, and hormonal characteristics. An up-dated approach to the clinical assessment of the patient with GHI focusing on investigation of the GH-IGF-I axis and relevant molecular studies contributing to the identification of causative genetic defects is also discussed.

AB - Human genetic defects in the growth hormone (GH)-IGF-I axis affecting the IGF system present with growth failure as their principal clinical feature. This is usually associated with GH insensitivity (GHI) presenting in childhood as severe or mild short stature. Dysmorphic features and metabolic abnormalities may also be present. The field of GHI due to mutations affecting GH action has evolved rapidly since the first description of the extreme phenotype related to homozygous GH receptor (GHR) mutations in 1966. A continuum of genetic, phenotypic, and biochemical abnormalities can be defined associated with clinically relevant defects in linear growth. The mechanisms of the GH-IGF-I axis in the regulation of normal human growth is discussed followed by descriptions of mutations in GHR, STAT5B, IGF-I, IGFALS, IGF1R, and GH1 defects causing bio-inactive GH or anti-GH antibodies. These GHIGF-I axis defects are associated with a range of clinical, and hormonal characteristics. An up-dated approach to the clinical assessment of the patient with GHI focusing on investigation of the GH-IGF-I axis and relevant molecular studies contributing to the identification of causative genetic defects is also discussed.

KW - Childhood linear growth

KW - Genetic defects

KW - Growth hormone insensitivity

KW - Growth hormone-IGF-I axis mutations

UR - http://www.scopus.com/inward/record.url?scp=84874376142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874376142&partnerID=8YFLogxK

U2 - 10.3389/fendo.2011.00095

DO - 10.3389/fendo.2011.00095

M3 - Article

C2 - 22654835

AN - SCOPUS:84874376142

VL - 2

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - DEC

M1 - Article 95

ER -